MONTREAL, CANADA--(Marketwire - September 02, 2008) - Theratechnologies (TSX: TH) today announced that the 52-week results from its first Phase 3 clinical trial, using tesamorelin, are published in the September 2, 2008 Journal of the International AIDS Society (www.aidsonline.com). The study entitled, “Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation” outlines, in detail, the 52-week data of the first Phase 3 trial. Top-line results were initially disclosed in October 2007.
